• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.隐匿性IIIA-N2期患者接受初始手术后总体生存率良好。
J Thorac Dis. 2018 Dec;10(12):6670-6676. doi: 10.21037/jtd.2018.10.94.
2
Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.IIIA期肺癌诱导治疗后的结节分期决定患者生存率。
Ann Thorac Surg. 2000 Dec;70(6):1826-31. doi: 10.1016/s0003-4975(00)01585-x.
3
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.非小细胞肺癌病理ⅢA期(N2)三联疗法后的疾病失败模式。癌症与白血病B组方案8935分析。
Cancer. 1996 Jun 1;77(11):2393-9. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
4
Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.基线可切除 IIIA-N2 期非小细胞肺癌的外科多模态治疗。纵隔淋巴结受累程度及对生存的影响。
Eur J Cardiothorac Surg. 2009 Sep;36(3):433-9. doi: 10.1016/j.ejcts.2009.04.013. Epub 2009 Jun 6.
5
Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.正电子发射断层扫描显示纵隔摄取阴性的非小细胞肺癌患者隐匿性纵隔淋巴结受累的模式及预测因素
Eur J Cardiothorac Surg. 2008 Jan;33(1):104-9. doi: 10.1016/j.ejcts.2007.09.026. Epub 2007 Oct 30.
6
Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.接受根治性手术的IIIA-N2期非小细胞肺癌患者在接受或未接受放疗的诱导化疗后,正电子发射断层扫描-计算机断层扫描的解读及预后价值
Medicine (Baltimore). 2015 Jun;94(24):e955. doi: 10.1097/MD.0000000000000955.
7
Surgical outcomes after initial surgery for clinical single-station N2 non-small-cell lung cancer.初治临床单站 N2 期非小细胞肺癌的手术治疗结果。
Jpn J Clin Oncol. 2014 Jan;44(1):85-92. doi: 10.1093/jjco/hyt164. Epub 2013 Nov 7.
8
Survival following resection of clinically occult N2 non small cell lung cancer.临床隐匿性N2期非小细胞肺癌切除术后的生存率
J Cardiovasc Surg (Torino). 1994 Dec;35(6 Suppl 1):13-7.
9
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.基于容积的18F-FDG PET/CT评估改善ⅢA-N2期非小细胞肺癌患者的预后预测
AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.
10
Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.III A-N2期非小细胞肺癌根治性切除术后转移pN2淋巴结数量的预后意义
Clin Lung Cancer. 2015 Nov;16(6):e203-12. doi: 10.1016/j.cllc.2015.04.004. Epub 2015 Apr 23.

引用本文的文献

1
Long-term outcomes of surgery in resectable single-station N2 non-small cell lung cancer patients.可切除的单站N2期非小细胞肺癌患者手术的长期预后
Turk Gogus Kalp Damar Cerrahisi Derg. 2025 Mar 26;33(2):205-216. doi: 10.5606/tgkdc.dergisi.2025.27229. eCollection 2025 Apr.
2
Occult lymph node metastasis is not a favorable factor for resected NSCLC patients.隐匿性淋巴结转移并非可切除 NSCLC 患者的有利因素。
BMC Cancer. 2023 Sep 4;23(1):822. doi: 10.1186/s12885-023-11189-3.
3
True Prevalence of Unforeseen N2 Disease in NSCLC: A Systematic Review + Meta-Analysis.非小细胞肺癌中意外N2期疾病的真实患病率:一项系统评价+荟萃分析
Cancers (Basel). 2023 Jul 3;15(13):3475. doi: 10.3390/cancers15133475.
4
Genomics Analysis and Nomogram Risk Prediction of Occult Lymph Node Metastasis in Non-Predominant Micropapillary Component of Lung Adenocarcinoma Measuring ≤ 3 cm.≤3 cm肺腺癌非优势微乳头成分中隐匿性淋巴结转移的基因组分析及列线图风险预测
Front Oncol. 2022 Jul 13;12:945997. doi: 10.3389/fonc.2022.945997. eCollection 2022.
5
Role of endobronchial ultrasound-guided transbronchial needle aspiration in staging of lung cancer: a thoracic surgeon's perspective.支气管内超声引导下经支气管针吸活检在肺癌分期中的作用:胸外科医生的观点
Mediastinum. 2021 Mar 25;5:2. doi: 10.21037/med-20-23. eCollection 2021.
6
Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study.PET/CT 定义的隐匿性淋巴结转移的肺癌预后良好,并从辅助治疗中获益:一项多中心研究。
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2414-2424. doi: 10.1007/s00259-022-05690-3. Epub 2022 Jan 20.
7
Heterogeneity of stage IIIA leads to difficulty in determining optimal treatment.IIIA期的异质性导致难以确定最佳治疗方案。
J Thorac Dis. 2019 Sep;11(Suppl 15):S2043-S2045. doi: 10.21037/jtd.2019.08.111.
8
Local control of locally advanced (N2) non-small cell lung cancer: when and how?局部晚期(N2)非小细胞肺癌的局部控制:时机与方式?
J Thorac Dis. 2019 May;11(Suppl 9):S1169-S1171. doi: 10.21037/jtd.2019.04.26.
9
Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!ⅢA-N2期非小细胞肺癌的手术治疗:尚无定论!
J Thorac Dis. 2019 May;11(Suppl 9):S1153-S1156. doi: 10.21037/jtd.2019.04.36.

本文引用的文献

1
Management of stage IIIA (N2) non-small cell lung cancer: A transatlantic perspective.ⅢA期(N2)非小细胞肺癌的治疗:跨大西洋视角
J Thorac Cardiovasc Surg. 2016 May;151(5):1235-8. doi: 10.1016/j.jtcvs.2016.01.035. Epub 2016 Mar 17.
2
Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.术后放疗治疗辅助化疗后病理 N2 期非小细胞肺癌:国家癌症数据库综述。
J Clin Oncol. 2015 Mar 10;33(8):870-6. doi: 10.1200/JCO.2014.58.5380. Epub 2015 Feb 9.
3
Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.在 IIIA 期 N2 非小细胞肺癌的治疗中,与根治性放化疗相比,新辅助放化疗联合手术可改善生存结局。
Eur J Cardiothorac Surg. 2015 Nov;48(5):684-90; discussion 690. doi: 10.1093/ejcts/ezu504. Epub 2015 Jan 6.
4
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.随机 III 期研究:手术单独治疗或手术联合术前顺铂和吉西他滨治疗 IB 期至 IIIA 期非小细胞肺癌。
J Clin Oncol. 2012 Jan 10;30(2):172-8. doi: 10.1200/JCO.2010.33.7089. Epub 2011 Nov 28.
5
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.随机对照试验:在 N0 或 N1(肺门淋巴结转移阴性)非小细胞肺癌患者的肺切除术中,纵隔淋巴结采样与完全淋巴结清扫的比较:美国外科医师学院肿瘤学组 Z0030 试验结果。
J Thorac Cardiovasc Surg. 2011 Mar;141(3):662-70. doi: 10.1016/j.jtcvs.2010.11.008.
6
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.早期非小细胞肺癌的术前化疗加手术与手术加辅助化疗与单纯手术比较。
J Clin Oncol. 2010 Jul 1;28(19):3138-45. doi: 10.1200/JCO.2009.27.6204. Epub 2010 Jun 1.
7
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.可手术非小细胞肺癌的辅助化疗,联合或不联合术后放疗:两项个体患者数据的荟萃分析。
Lancet. 2010 Apr 10;375(9722):1267-77. doi: 10.1016/S0140-6736(10)60059-1. Epub 2010 Mar 24.
8
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.肺癌辅助顺铂评估:LACE协作组的汇总分析
J Clin Oncol. 2008 Jul 20;26(21):3552-9. doi: 10.1200/JCO.2007.13.9030. Epub 2008 May 27.
9
Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.正电子发射断层扫描显示纵隔摄取阴性的非小细胞肺癌患者隐匿性纵隔淋巴结受累的模式及预测因素
Eur J Cardiothorac Surg. 2008 Jan;33(1):104-9. doi: 10.1016/j.ejcts.2007.09.026. Epub 2007 Oct 30.
10
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.国际肺癌研究协会肺癌分期项目:关于在即将出版的(第七版)《恶性肿瘤TNM分类》中修订TNM分期分组的建议。
J Thorac Oncol. 2007 Aug;2(8):706-14. doi: 10.1097/JTO.0b013e31812f3c1a.

隐匿性IIIA-N2期患者接受初始手术后总体生存率良好。

Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.

作者信息

Kim Min P, Correa Arlene M, Hofstetter Wayne L, Mehran Reza J, Rice David C, Roth Jack A, Vaporciyan Ara A, Walsh Garrett L, Erasmus Jeremy J, Swisher Stephen G

机构信息

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Division of Thoracic Surgery, Department of Surgery, Houston Methodist, Houston, Texas, USA.

出版信息

J Thorac Dis. 2018 Dec;10(12):6670-6676. doi: 10.21037/jtd.2018.10.94.

DOI:10.21037/jtd.2018.10.94
PMID:30746212
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6344762/
Abstract

BACKGROUND

Patients may be found to have stage IIIA-N2 at the final pathology after the initial surgery. We want to determine the survival rate in this unique group of patients.

METHODS

We reviewed all patients who underwent surgical resection for lung cancer from 2000 to 2011 who had pathologic stage N2 without induction therapy. We determined the clinicopathologic characteristics and survival rate in this unique group of patients.

RESULTS

A total of 101 patients met the inclusion criteria. The average age of the group was 65 years old with 53 (53%) females. The chest computed tomography (CT) scans showed 30 patients (30%) with mediastinal lymphadenopathy (>1 cm) and 13 (13%) with multistation disease. The positron emission tomography-computed tomography (PET-CT) showed 24 patients (24%) with N2 positive uptake. Invasive mediastinal staging prior to surgery occurred in 43 patients (43%). Eighty-four patients underwent a lobectomy (83%), 7 with bilobectomy (7%), and 10 with pneumonectomy (10%). The most common pathology was adenocarcinoma with 73 patients (72%) and the second most common was squamous cell carcinoma with 22 patients (22%). Most of the patients completed the adjuvant chemoradiation therapy (86%). The 5-year survival rate was 48% and the 10-year survival rate was 24%.

CONCLUSIONS

Pathologic stage IIIA-N2 non-small cell lung cancer (NSCLC) is a heterogeneous disease process with a very small group of patients undergoing initial surgery. Patients with occult stage IIIA-N2 who undergo initial surgery have an excellent overall survival rate.

摘要

背景

患者在初次手术后的最终病理检查中可能被发现处于IIIA-N2期。我们想要确定这一独特患者群体的生存率。

方法

我们回顾了2000年至2011年期间接受肺癌手术切除且病理分期为N2期且未接受诱导治疗的所有患者。我们确定了这一独特患者群体的临床病理特征和生存率。

结果

共有101例患者符合纳入标准。该组患者的平均年龄为65岁,其中女性53例(53%)。胸部计算机断层扫描(CT)显示30例患者(30%)有纵隔淋巴结肿大(>1 cm),13例(13%)有多站病变。正电子发射断层扫描-计算机断层扫描(PET-CT)显示24例患者(24%)N2摄取阳性。43例患者(43%)在手术前行有创纵隔分期。84例患者接受了肺叶切除术(83%),7例接受了双肺叶切除术(7%),10例接受了全肺切除术(10%)。最常见的病理类型是腺癌,有73例患者(72%),第二常见的是鳞状细胞癌,有22例患者(占22%)。大多数患者完成了辅助放化疗(86%)。5年生存率为48%,10年生存率为24%。

结论

病理IIIA-N2期非小细胞肺癌(NSCLC)是一种异质性疾病过程,仅有一小部分患者接受初次手术。接受初次手术的隐匿性IIIA-N2期患者总体生存率良好。